Equillium raises $30M in private placement; cash runway through 2027

Equillium, Inc.

Initial closing of 21.8M shares at $0.57/sh and pre-funded warrants for 30.8M shares, gross proceeds $30M.
Potential milestone closing of up to $20M upon IND clearance or first patient dosing for EQ504 and stock price threshold.
Net proceeds expected to extend cash runway through 2027, prioritizing EQ504 development.
Company has not initiated cryptocurrency treasury reserve strategy as previously announced.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.